Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
NEJM 378:708-718, Albers, G.W.,et al, 2018
Acute Spinal Cord Compression
NEJM 376:1358-1369, Ropper, A.E. & Ropper, A.H., 2017
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
The Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale
Stroke 43:2871-2876, Pescini, F.,et al, 2012
Cortical Lesions in Primary Progressive Multiple Sclerosis: A 2-Year Longitudinal MR Study
Neurol 72:1330-1336, Calabrese,M.,et al, 2009
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Relative Contributions of Brain and Cervical Cord Pathology to Multiple Sclerosis Disability: a Study with Magnetisation Transfer Ratio Histogram Analysis
JNNP 69:723-727, Rovaris,M.,et al, 2000
Early Clinical and Radiological Predictors of Fatal Brain Swelling in Ischemic Stroke
Stroke 30:287-292, Krieger,D.W.,et al, 1999
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Correlation of Perfusion-and Diffusion-Weighted MRI with NIHSS Score in Acute (<6. 5 hr) Ischemic Stroke
Neurol 50:864-870, 8421998., Tong,D.C.,et al, 1998
Intracranial Aneurysms
NEJM 336:28-40, Schievink,W.I., 1997
Paramedian Pontine Infarction
Stroke 28:809-815, Kataoka,S.,et al, 1997
Ischemic Lesion Volumes in Acute Stroke by Diffusion-Weighted MRI Correlate with Clinical Outcome
Ann Neurol 42:164-170, Lovblad,K-O.,et al, 1997
Prognostic Value of the Hyperdense Middle Cerebral Artery Sign and Stroke Scale Score Before Ultraearly Thrombolytic Therapy
AJNR 17:79-85, Tomsick,T.,et al, 1996
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Correlation Between Changes in Disability and T2-Weighted Brain MRI Activity in Multiple Sclerosis:A Follow-up Study
Neurol 45:255-260, Filippi,M.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
Interferon Beta-1b is Effective in Relapsing-Remitting MS
Clinical Results of a Placebo-Controlled Trial, IFNB MS Study Grp, Neurol 43:655-661, 64193., , 1993
Interferon Beta-1b is Effective in Relapsing Remitting MS, MRI Analysis Results of Placebo-Control Trial
Neurol 43:662-667, 6411993., Paty,D.W.,et al, 1993
Cognitive Loss in Multiple Sclerosis
Arch Neurol 46:162-167, Franklin,G.M.,et al, 1989